Press Releases

Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24

Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

Panbela Announces Publication of Abstract: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

Panbela Provides Business Update and Reports Q3 2023 Financial Results

Panbela Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9M Gross Proceeds Priced At-the-Market

Panbela Announces Publication of Preclinical and Clinical Data: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.

Panbela Announces Validation of European Patent for Claims of a Novel Process for the Production of SBP-101

Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication